United States - English - NLM (National Library of Medicine)

the medicines company - cangrelor (unii: 6aq1y404u7) (cangrelor - unii:6aq1y404u7) - cangrelor 50 mg - kengreal is indicated as an adjunct to percutaneous coronary intervention (pci) to reduce the risk of periprocedural myocardial infarction (mi), repeat coronary revascularization, and stent thrombosis (st) in patients who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iib/iiia inhibitor [see clinical studies ( 14.1 )]. kengreal is contraindicated in patients with significant active bleeding [see warnings and precautions ( 5.1 ) and adverse reactions ( 6.1 )] . kengreal is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to kengreal or any component of the product [see adverse reactions ( 6.1 )] . pregnancy category c there are no adequate and well-controlled studies of kengreal in pregnant women. cangrelor did not produce malformations in either the rat or rabbit reproductive studies, and is not considered to be a teratogen. in embryo-fetal development studies in rats, cangrelor produced dose-related fetal growth retardation characteri

United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - cangrelor (unii: 6aq1y404u7) (cangrelor - unii:6aq1y404u7) - cangrelor 50 mg - kengreal is indicated as an adjunct to percutaneous coronary intervention (pci) to reduce the risk of periprocedural myocardial infarction (mi), repeat coronary revascularization, and stent thrombosis (st) in patients who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iib/iiia inhibitor [see clinical studies ( 14.1 )]. kengreal is contraindicated in patients with significant active bleeding [see warnings and precautions ( 5.1 ) and adverse reactions ( 6.1 )] . kengreal is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to kengreal or any component of the product [see adverse reactions ( 6.1 )] . risk summary there are no available data on cangrelor use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. untreated myocardial infarction can be fatal to the pregnant women and fetus (see clinical considerations ). in animal reproduction studies, continuous inf

Canada - English - Health Canada

chiesi farmaceutici s.p.a. - cangrelor (cangrelor tetrasodium) - powder for solution - 50mg - cangrelor (cangrelor tetrasodium) 50mg

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antithrombotic agents - kengrexal, co-administered with acetylsalicylic acid (asa), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (pci) who have not received an oral p2y12 inhibitor prior to the pci procedure and in whom oral therapy with p2y12 inhibitors is not feasible or desirable.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - cangrelor tetrasodium - powder for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - cangrelor tetrasodium - powder for solution for injection - 50mg

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - ticagrelor (unii: glh0314rvc) (ticagrelor - unii:glh0314rvc) - ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction (mi), and stroke in patients with acute coronary syndrome (acs) or a history of mi. for at least the first 12 months following acs, it is superior to clopidogrel. ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of acs [see clinical studies (14.1)] . ticagrelor tablets are indicated to reduce the risk of a first mi or stroke in patients with coronary artery disease (cad) at high risk for such events [see clinical studies (14.2)]. while use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (t2dm). ticagrelor tablets are contraindicated in patients with a history of intracranial hemorrhage (ich) because of a high risk of recurrent ich in this population [see clinical studies (14.1), (14.2)] . ticagrelor tablets are contraindicated in patients with active pathological bleeding

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - ticagrelor - film-coated tablet - 60 milligram(s) - ticagrelor

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - ticagrelor - film-coated tablet - 90 milligram(s) - ticagrelor